Sands Capital Management LLC Has $300.11 Million Stake in argenex SE $ARGX

Sands Capital Management LLC boosted its holdings in shares of argenex SE (NASDAQ:ARGX) by 2,046.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 356,870 shares of the company’s stock after purchasing an additional 340,245 shares during the period. Sands Capital Management LLC owned 0.58% of argenex worth $300,110,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ARGX. AQR Capital Management LLC increased its stake in shares of argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC increased its stake in shares of argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after buying an additional 1,431 shares during the period. Focus Partners Wealth increased its stake in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after buying an additional 73 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after buying an additional 50 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Price Performance

Shares of argenex stock opened at $893.52 on Monday. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The business has a fifty day simple moving average of $812.09 and a 200 day simple moving average of $811.50. The stock has a market cap of $55.57 billion, a PE ratio of 39.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The business had revenue of $1.31 billion during the quarter. Analysts expect that argenex SE will post 26.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ARGX has been the subject of several research reports. Citizens Jmp lifted their target price on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. HC Wainwright lifted their price objective on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Guggenheim lifted their price objective on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.